Healthtech Series C Investors & VC Firms

771 firms in this list, with a median first check of $1M. 164 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
CA Catalyst Health Ventures DZJSDMJL8 people · Leads rounds	88🔒	Boston	US	Seed–Series C	$1M – $3M	+ Add to CRM
FU Fundamentum AKNNSAPJ4 people · Leads rounds	88🔒	Gurugram	IN	Series B–Series C	$10M – $25M	+ Add to CRM
SH Shepherd Ventures GCRPTSFD6 people · Leads rounds	88🔒	San Diego	US	Series A–Late Stage	$750K – $3M	+ Add to CRM
CH Cheyenne Ventures GEJFJBRL4 people · Leads rounds	88🔒	Woodside	US	Series A–Late Stage	—	+ Add to CRM
RA Radix Ventures PBMUWRAM9 people · Follows rounds	88🔒	Warsaw	PL	Seed–Late Stage	$550K – $2.8M	+ Add to CRM
VI Vision Incubate HNKMMTKS9 people	88🔒	Kanazawa	JP	Pre-Seed–Growth	—	+ Add to CRM
KO Korea Investment Partners DJJHJHMS17 people	88🔒	Seoul	KR	Seed–Late Stage	$973K – $50M	+ Add to CRM
VN VNV Global BV1 person · Leads rounds	88🔒	Stockholm	SE	Pre-Seed–Late Stage	—	+ Add to CRM
CI Cinven	88🔒	London	GB	Series B–Late Stage	—	+ Add to CRM
PR Prospect Venture Partners AEDSRH3 people · Leads rounds	88🔒	Menlo Park	US	Seed–Late Stage	$3M – $5M	+ Add to CRM
LE LEAD ANABBTJP11 people · Follows rounds	88🔒	Orlando	US	Pre-Seed–Late Stage	$100K – $1M	+ Add to CRM
RH RH Managers QZCCDDAM14 people	88🔒	Johannesburg	ZA	Seed–Late Stage	—	+ Add to CRM
SO Sodero AACVMSRE11 people	88🔒	Nantes	FR	Seed–Late Stage	$162K – $5.4M	+ Add to CRM
NE Nelstone Ventures RN1 person	88🔒	—		Series C	—	+ Add to CRM
VI Vital Venture Capital ACNCNLCA5 people · Leads rounds	88🔒	Washington	US	Series A–Growth	$1M – $3M	+ Add to CRM
LU Luma Group JFTKJKNM13 people	88🔒	Boston	US	Seed–Late Stage	—	+ Add to CRM
PI Pivotal Life Sciences GBAVBMJL13 people	88🔒	San Francisco	US	Seed–Late Stage	—	+ Add to CRM
GL Glisco Partners ACCSJLRE13 people	88🔒	Mexico City	MX	Series B–Late Stage	—	+ Add to CRM
OL Oltre Impact LBLANLRF10 people	88🔒	Milan	IT	Seed–Late Stage	$2.2M – $8.6M	+ Add to CRM
QC QC·VENTURES FSMUTBAC7 people	88🔒	Vienna	AT	Seed–Late Stage	$216K – $4.3M	+ Add to CRM
BL Blackstone Life Sciences NGABBGCF9 people	88🔒	New York	US	Series A–Late Stage	$20M – $60M	+ Add to CRM
EU Eurazeo LGLMMTNW12 people	88🔒	Paris	FR	Series A–Late Stage	—	+ Add to CRM
LS LSP (Life Sciences Partners) PSRRRDDB8 people · Leads rounds	88🔒	Amsterdam	NL	Series A–Late Stage	$10.8M – $64.8M	+ Add to CRM
KA Kama Flow EBKT2 people	88🔒	Moscow	RU	Seed–Late Stage	—	+ Add to CRM

Catalyst Health Ventures

BostonSeed–Series C$1M – $3M

DZJSDMJL8 people

Fundamentum

GurugramSeries B–Series C$10M – $25M

AKNNSAPJ4 people

Shepherd Ventures

San DiegoSeries A–Late Stage$750K – $3M

GCRPTSFD6 people

Cheyenne Ventures

WoodsideSeries A–Late Stage

GEJFJBRL4 people

Radix Ventures

WarsawSeed–Late Stage$550K – $2.8M

PBMUWRAM9 people

Vision Incubate

KanazawaPre-Seed–Growth

HNKMMTKS9 people

Korea Investment Partners

SeoulSeed–Late Stage$973K – $50M

DJJHJHMS17 people

VNV Global

StockholmPre-Seed–Late Stage

BV1 person

Cinven

LondonSeries B–Late Stage

Prospect Venture Partners

Menlo ParkSeed–Late Stage$3M – $5M

AEDSRH3 people

LEAD

OrlandoPre-Seed–Late Stage$100K – $1M

ANABBTJP11 people

RH Managers

JohannesburgSeed–Late Stage

QZCCDDAM14 people

Sodero

NantesSeed–Late Stage$162K – $5.4M

AACVMSRE11 people

Nelstone Ventures

Series C

RN1 person

Vital Venture Capital

WashingtonSeries A–Growth$1M – $3M

ACNCNLCA5 people

Luma Group

BostonSeed–Late Stage

JFTKJKNM13 people

Pivotal Life Sciences

San FranciscoSeed–Late Stage

GBAVBMJL13 people

Glisco Partners

Mexico CitySeries B–Late Stage

ACCSJLRE13 people

Oltre Impact

MilanSeed–Late Stage$2.2M – $8.6M

LBLANLRF10 people

QC·VENTURES

ViennaSeed–Late Stage$216K – $4.3M

FSMUTBAC7 people

Blackstone Life Sciences

New YorkSeries A–Late Stage$20M – $60M

NGABBGCF9 people

Eurazeo

ParisSeries A–Late Stage

LGLMMTNW12 people

LSP (Life Sciences Partners)

AmsterdamSeries A–Late Stage$10.8M – $64.8M

PSRRRDDB8 people

Kama Flow

MoscowSeed–Late Stage

EBKT2 people

Data sourced from public filings and firms' own websites — see our methodology.